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Trafficking of Endogenous 
Immunoglobulins by Endothelial 
Cells at the Blood-Brain Barrier
Roberto Villaseñor1, Laurence Ozmen1, Nadia Messaddeq2, Fiona Grüninger1, 
Hansruedi Loetscher1, Annika Keller3, Christer Betsholtz4,5, Per-Ola Freskgård1  
& Ludovic Collin1
The Blood-Brain Barrier (BBB) restricts access of large molecules to the brain. The low endocytic activity 
of brain endothelial cells (BECs) is believed to limit delivery of immunoglobulins (IgG) to the brain 
parenchyma. Here, we report that endogenous mouse IgG are localized within intracellular vesicles 
at steady state in BECs in vivo. Using high-resolution quantitative microscopy, we found a fraction 
of endocytosed IgG in lysosomes. We observed that loss of pericytes (key components of the BBB) 
in pdgf-bret/ret mice affects the intracellular distribution of endogenous mouse IgG in BECs. In these 
mice, endogenous IgG was not detected within lysosomes but instead accumulate at the basement 
membrane and brain parenchyma. Such IgG accumulation could be due to reduced lysosomal clearance 
and increased sorting to the abluminal membrane of BECs. Our results suggest that, in addition to low 
uptake from circulation, IgG lysosomal degradation may be a downstream mechanism by which BECs 
further restrict IgG access to the brain.
Therapeutic antibodies hold considerable potential in both diagnosis and treatment of diseases1,2. However, their 
use for passive or active immunotherapy in the central nervous system (CNS) is limited by the blood–brain bar-
rier (BBB). It is estimated that the BBB prevents over 95% of drugs, including large molecules such as immuno-
globulins (IgG), from accessing the brain3. In mice, less than 0.1% of peripherally administered IgG reaches the 
brain parenchyma4. This function of the BBB is critical for maintenance of brain homeostasis and results from the 
unique properties of brain endothelial cells (BECs). These cells are distinguished from peripheral endothelial cells 
by the presence of particularly tight intercellular junctions that prevent paracellular transport, by the expression 
of specialized molecular transporters and receptors at the apical and basolateral membranes and by a higher peri-
cyte coverage. Furthermore, they interact with CNS-specific cell types, such as astrocytes, microglia and neurons, 
which together form the functional neurovascular unit (NVU)5–7. The precise role of BECs in protecting the brain 
from peripheral protein influx has been extensively studied. However, intracellular sorting and transport through 
the transcytosis pathway in BECs remains largely unexplored8.
Morphological studies of the BBB using transmission electron microscopy (TEM) showed that exogenous 
horseradish peroxidase (HRP) was poorly internalized within BECs9. This observation led to the widely held view 
that a low rate of endocytosis is a hallmark of the BBB3,5,6. Specifically, it is believed that “minimal vesicular traf-
ficking”10 may be responsible for minimizing the amount of IgG that reaches the brain parenchyma11. However, 
additional mechanisms downstream of uptake may be involved. Despite extensive research on the delivery of 
therapeutic antibodies to the brain, surprisingly little is known about transcytosis of IgG4,12–14. Most studies focus-
ing on uptake and sorting of IgG have been performed in cultured cells and data showing that IgG is present 
within BECs in situ in the NVU is limited15.
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In this study, we investigated the distribution of IgG at the BBB and in BECs. By using quantitative 
high-resolution confocal microscopy, we show for the first time that endogenous mouse IgG (mIgG), one of the 
main components of plasma16, is present in intracellular vesicles within BECs. At steady state, a fraction of mIgG 
is found in lysosomes. We observed that loss of pericytes in pdgf-bret/ret mice17 affects the intracellular distribution 
of endogenous mIgG and of a peripherally administered antibody in BECs. Our data suggest that pericytes mod-
ulate IgG trafficking by reducing their lysosomal transport in BECs. Overall, our results suggest that, in addition 
to a low basal rate of uptake, lysosomal degradation of IgG is a downstream mechanism by which BECs may limit 
the amount of IgG that enters the brain.
Results
We first applied a confocal light-microscopy protocol to image different cell types of the NVU. Our aim was to 
visualize intracellular structures that could thus far be detected only by electron microscopy (Fig. 1a). We recon-
structed a 3D model of the NVU by immunofluorescent-labelling of BECs, pericytes and basal lamina markers 
(Fig. 1b,c; Table 1). Next, we examined the distribution of endogenous mIgG within the NVU. Under physiolog-
ical conditions, it is believed that the low endocytosis rate of BECs is sufficient to exclude mIgG from the brain 
parenchyma11. Unexpectedly, we detected numerous mIgG puncta within capillaries (Fig. 1d–f; Supplementary 
Video 1). This distribution of mIgG was not an artefact caused by unspecific antibody binding since (i) we 
observed the same pattern using three different anti-mouse antibodies (Fig. 1d,g–j, Supplementary Fig. 1), (ii) 
no signal was observed using secondary antibodies against goat or human IgGs (Supplementary Figs 1 and 5), 
and (iii) the signal was restricted to the intracellular space in capillaries delineated by CollagenIV (Fig. 1d–f). 
We found that the distribution of mIgG was widespread along the vasculature in the cerebral cortex. However, 
the punctate pattern of mIgG was only evident at high-resolution (Supplementary Fig. 2). The majority of these 
puncta occurred within BECs and not pericytes, as shown by staining with CD31 (Fig. 1g,h) or CD13 (Fig. 1i,j).
The mIgG puncta had a radius between 0.2 and 0.4 μ m with the majority below 0.5 μ m, in agreement with the 
size of endosomes (Fig. 1k, Supplementary Fig. 3). We also estimated the amount of mIgG contained in individual 
puncta by quantifying the fluorescence intensity per puncta. Intensity values corresponding to individual puncta 
spanned nearly three orders of magnitude (Fig. 1l) suggesting that some puncta accumulate mIgG18.
Next, we analyzed the localization of mIgG within BECs. Extensive antibody screening was performed to 
identify suitable endosomal markers compatible with our ex vivo technique. However, many antibodies gave 
non-specific punctate staining and were not considered for further analysis. As an alternative we exploited two 
recently described “Brain Shuttle” antibodies as markers of different endosomal populations19. Monovalent 
Brain Shuttle (BS-sFab) binds to the transferrin receptor (TfR) and is trafficked through the transferrin 
receptor-mediated transcytosis pathway, which includes both early and recycling endosomes, ultimately reach-
ing the brain parenchymal space. Divalent Brain Shuttle (BS-dFab) also binds to the transferrin receptor but is 
trafficked for degradation in lysosomes19. The Brain Shuttles were detected using a secondary antibody against 
human IgG. Mice were administered with the different BS constructs (6 mg/kg) and sacrificed either 30 minutes 
(BS-sFab) or 8 hours (BS-dFab) post-injection. After 8 hours, BS-sFab is localized in the brain parenchyma with 
only minimal signal in capillaries and was thus not suitable for this analysis19. We found BS-sFab in vesicular 
structures within capillaries (Fig. 2a). Interestingly, we observed colocalization between BS-sFab and mIgG in 
vesicles close to the luminal membrane (Fig. 2a, asterisk). In contrast, there was little overlap between BS-sFab- 
and large mIgG-positive vesicles (Fig. 2a, arrows), suggesting that BS-sFab and mIgG are initially transported 
through a common endosomal compartment and that mIgG is subsequently sorted away from the canonical 
TfR transcytosis pathway. On the other hand, we observed extensive colocalization between BS-dFab and mIgG 
(Fig. 2b). Since BS-dFab is sorted to lysosomes this suggested that mIgG-positive vesicles are also transported 
to lysosomes19. To confirm this hypothesis, we performed a double immunostaining using an antibody against 
LAMP2, a lysosomal marker, and mIgG. We found that 20% of the total intracellular mIgG colocalized with lys-
osomes at steady state (Fig. 2c,d). In BECs, therefore, a substantial amount of mIgG is transported to lysosomes 
for degradation.
Pericytes are key components of the NVU that are known to control the permeability of the BBB. Previous 
work showed that reduction of pericyte coverage of brain microcapillaries in pdgf-bret/ret mice results in the acute 
extravasation of injected tracers due to increased transcytosis17. However, the specific changes in the transcy-
tosis pathway (for example uptake, sorting or fusion with the plasma membrane) were not explored. Therefore, 
we applied our imaging and quantification protocol to analyze the changes in endogenous mIgG transport in 
pdgf-bret/ret mice in comparison to control mice (Fig. 3a–c). We used CollagenIV, a marker of the basal lamina, 
to delineate capillaries in 3D and then quantified the amount of mIgG that accumulated within the basal lam-
ina, the amount of mIgG that accumulated in the brain parenchymal space and the number of mIgG-positive 
vesicles contained within microcapillaries (Fig. 3d–f, respectively). The amount of endogenous mIgG increased 
100-fold within the basal lamina and 50-fold in the brain parenchymal space of pdgf-bret/ret mice compared to 
both C57BL/6 and pdgf-bret/wt mice (Fig. 3a–e, Supplementary Fig. 4). The enlargement of capillaries in pdgf-bret/ret  
was previously reported (Fig. 3c)17. Strikingly, the number of mIgG-positive intracellular vesicular structures was 
significantly reduced in pdgf-bret/ret mice compared to C57BL/6 or pdgf-bret/wt mice (Fig. 3f). Moreover, the few 
remaining vesicular structures did not colocalize with LAMP2-positive lysosomes (Fig. 3g, inset and arrows). 
Therefore, the reduced number of intracellular mIgG-positive vesicles in pdgf-bret/ret mice could result from the 
increased transport and delivery of mIgG to the abluminal membrane.
To test this hypothesis, we used TEM to analyze the distribution of the total pool of intracellular vesicles in 
pdgf-bret/ret mice (Fig. 4a). Vesicles were classified as (i) luminal, including coated and non-coated vesicles docked 
or budding from the luminal membrane (Fig. 4b), (ii) intracellular, including tubules and vesicles within the cyto-
plasm (Fig. 4c) or (iii) abluminal i.e. vesicles docked to the abluminal membrane (Fig. 4d). There was no signifi-
cant difference between luminal vesicles in pdgf-bret/ret and pdgf-bret/wt mice (Fig. 4e). However, both the number of 
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Figure 1. Intracellular localization of endogenous mIgG in brain endothelial cells. (a) Representative 
TEM cross-section of a brain cortical microvessel. The arrow points to a non-coated vesicle budding from the 
luminal membrane, the arrowhead points to a clathrin-coated-vesicle and the asterisk marks an intracellular 
vesicle. BEC, Brain Endothelial Cell; TJ, Tight Junction; BL, Basal Lamina; Per, Pericyte. (b,c) Representative 
3D reconstruction of the NVU showing a BEC (marked by CD31 expression, green), Pericyte (marked by 
CD13 expression, red) within the Basal Lamina (CollagenIV, grey). The cross-section in the right panel (c) is a 
single optical section to highlight the vascular lumen. (d–f) Representative 3D reconstruction of a microvessel 
(marked by CollagenIV, green) with mIgG (red) in punctate structures (d). (e) shows a high magnification 3D 
reconstruction of the boxed area. Cross-sections in (f) show that vesicles are within the Basal Lamina and not in 
the parenchymal space. (g–j) Representative single optical sections of mIgG puncta localizing specifically within 
BECs marked with CD31 in green (g,h) but not in pericytes marked with CD13 in green (i,j). (k,l) Histograms 
for the radius of mIgG-positive intracellular vesicles (k) and normalized mIgG intensity per vesicle (l) in semi-
logarithmic scale. Points show the mean value ± SEM of each size or intensity bin for 30 microvessels from 3 
different C57BL/6 mice. The continuous line shows a log-normal fit of the experimental data. In all images, 
DAPI-stained nuclei are shown in blue.
www.nature.com/scientificreports/
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intracellular and abluminal vesicles were significantly increased in pdgf-bret/ret BECs (Fig. 4f,g). These observations 
suggest that the increased delivery of endogenous mIgG to the brain parenchyma upon pericyte depletion results 
from an increased intracellular transport to the abluminal membrane.
To further confirm these data, we investigated the intracellular distribution in BECs of a human IgG following 
peripheral administration to pdgf-bret/ret and pdgf-bret/wt mice. Mab86 is a humanized antibody that binds spe-
cifically to phosphorylated tau20. One hour post-injection, Mab86 was localized within vesicular structures in 
pdgf-bret/wt BECs where it colocalized with endogenous mIgG (Fig. 5a, Supplementary Fig. 5). On the contrary, we 
did not detect Mab86-containing vesicular structures in pdgf-b ret/ret BECs (Fig. 5b).
Finally, we generated a new mouse model by crossing pdgf-b ret/ret animals with the TauPS2APP triple trans-
genic mouse model (3Tg) of Alzheimer’s Disease (AD)21 to test whether pericyte loss would increase transcytosis 
and delivery of Mab86 to phosphotau-containing hippocampal neurons. We injected 13 months-old mice i.p. 
with 30 mg/kg of Mab86 and analyzed brain sections 48 hours post-injection. Neither Mab86 nor mIgG were 
detectable in the brain parenchyma of 3Tg x pdgf-bret/wt mice (Fig. 5c). In 3Tg x pdgf-bret/ret mice, Mab86 and mIgG 
diffusely localized in the parenchymal space (Fig. 5d). However, Mab86 specifically accumulated in hippocampal 
neurons (Fig. 5d). We then examined tau pathology in the hippocampus of 3Tg x pdgf-bret/wt and 3Tg x pdgf-bret/ret 
mice and found that phosphotau localized predominantly at the tip of the CA1 region and the subiculum as pre-
viously described (Fig. 5e,f)20,21. In 3Tg.x pdgf-bret/wt mice, very few Mab86-positive cells were detected (Fig. 5e,g). 
However, Mab86 target engagement was strongly enhanced in phosphotau positive neurons of 3Tg x pdgf-bret/ret 
mice (Fig. 5f–h). These data confirm that pericyte depletion increases the delivery of a functional IgG to the brain. 
Overall, our results support the hypothesis that increased IgG transcytosis to the brain in pdgf-bret/ret mice results 
from an increased intracellular trafficking to the abluminal membrane.
Discussion
Earlier studies using electron microscopy showed that vesicular transport is extremely low in BECs, providing 
one possible explanation for how the BBB limits entry of peripheral proteins to the brain3,5,9. However, although 
TEM allows detailed characterization of the morphological properties of BECs and the NVU, it has limitations 
for the study of transcytosis. In particular, the number of intracellular vesicles within endothelial cells observed 
by TEM gives no information on the rates of endosome transport. A recent review on TEM studies found only 
a weak correlation between intracellular vesicles and transport capacity in different types of vascular bed22. This 
consideration prompted us to further investigate the mechanisms that restrict protein transport into the brain 
parenchyma.
We used TEM to quantify the total number of vesicular structures contained within BECs in pdgf-bret/ret and 
pdgf-bret/wt mice. Whereas luminal vesicle numbers were similar in pdgf-bret/ret and pdgf-bret/wt mice, pericyte loss 
in pdgf-bret/ret mice leads to increased numbers of intracellular vesicles. Docking and fusion of these vesicles with 
the abluminal membrane probably contributes to the increased protein permeability of the BBB as previously 
described17. To complement this analysis, we tried to identify the specific location of endogenous IgG at the NVU 
using quantitative high-resolution confocal imaging. In control mice, BECs contained numerous intracellular 
vesicles filled with varying amounts of mIgG. The steady state vesicular distribution observed ex vivo reflects the 
balance of uptake, endosome fusion, recycling, and degradation that has previously been described in in vitro 
models for cargo(s) such as LDL18. Importantly, our observations do not challenge the fact that BECs have a low 
basal uptake from circulation compared with peripheral endothelial cells. However, despite such a low uptake 
there are abundant mIgG-positive vesicles in BECs. Therefore, mechanisms downstream of uptake must exist 
to prevent the delivery of this intracellular mIgG pool to the brain parenchyma. First, mIgG may interact with 
FcRn and get recycled to the plasma membrane and released in the blood stream. FcRn is the only Fc receptor 
known to be expressed by BECs23. In vitro, FcRn-expressing endothelial cells can recycle IgG via Rab11-positive 
endosomes15. Therefore, binding of mIgG to FcRn within BEC endosomes could prevent their sorting to the ablu-
minal membrane. Additional experiments using specific markers of FcRn recycling pathway would be required 
to confirm this hypothesis. Second, mIgG may be prevented from reaching the parenchyma through trafficking 
to lysosomes for degradation. In a series of in vivo experiments, Broadwell et al showed that circulatory proteins 
are endocytosed and eventually degraded in lysosomes24. Interestingly, we observed significant colocalization of 
mIgG with both LAMP2 (a lysosomal marker) and BS-dFab (gets trafficked to lysosomes) indicating that lysoso-
mal degradation prevents delivery of mIgG to the brain. Together, these data suggest that lysosomal clearance of 
proteins in BECs may limit protein access to the brain parenchyma. Additional work using quantitative analysis 
of transport kinetics across multiple endosomal compartments in vivo will be required to fully characterize the 
sorting pathway for IgG across the BBB.
Cell Type or Antigen Antibody manufacturer
BECs (CD31/PECAM) Rat monoclonal MEC13.3, Novus Biologicals
Pericytes (CD13) Goat polyclonal, R&D Systems
Basal Lamina (CollagenIV) Rabbit polyclonal, Serotec
Lysosomes (LAMP2) Rat monoclonal ABL93, Fitzgerald
mIgG Donkey anti-mouse IgG (H + L) AlexaFluor594, LifeTechnologies. Donkey anti-mouse IgG (H + L) AlexaFluor488, LifeTechnologies. Goat anti-mouse IgG (H + L) AlexaFluor555, LifeTechnologies
Brain Shuttle (huIgG) Goat anti-human IgG (H + L) AlexaFluor555, LifeTechnologies. Goat anti-human IgG (H + L) AlexaFluor488, LifeTechnologies
Table 1.  List of validated antibodies for immunofluorescence staining of free-floating sections.
www.nature.com/scientificreports/
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Previous work showed that pericytes are key regulators of BBB permeability17,25. For example, the transcytosis 
flux is increased in pericyte-deficient mice such as pdgf-bret/ret17. We observed a significant reduction in the num-
ber of intracellular mIgG-positive vesicles in pdgf-bret/ret mice compared to control mice. Conversely, mIgG deliv-
ery to the brain was significantly increased. This could be due to an unchanged, saturated IgG uptake together 
with an increased release of mIgG to the brain in pdgf-bret/ret BECs13. Supporting this hypothesis we found (i) no 
difference in the number of luminal coated and non-coated vesicles and (ii) a significant increase in the number of 
abluminal vesicles in pdgf-bret/ret mice compared to control mice. These data suggest that pericyte loss may lead to 
increased vesicular flux to the abluminal membrane of BECs. The findings do not exclude that other fluid-phase 
uptake pathways26 are altered upon pericyte depletion25,27 but suggest that pericytes act on specific endocytosis 
pathways.
Figure 2. Endogenous mIgG localizes to lysosomes in BECs. (a,b) Representative 3D reconstruction of the 
intracellular distribution of the Brain Shuttle sFab (a) or dFab (b) (both in green) and endogenous mIgG (red) 
within a single brain microvessel. The right panels show high magnification image of the boxed area. Arrows 
highlight the minimal overlap between mIgG and BS-sFab vesicles in (a) and extensive colocalization between 
mIgG and BS-dFab in (b). Asterisks show Brain Shuttle-positive vesicles overlapping with faint mIgG vesicles. 
(c) Representative 3D reconstruction of the intracellular distribution of LAMP2-positive lysosomes (green) and 
endogenous mIgG (red) within a single brain microvessel. The right panel shows a high magnification image of 
the boxed area and highlights the colocalization between mIgG and LAMP2-positive lysosomes. In all images, 
DAPI-stained nuclei are shown in blue. (d) Colocalization of mIgG to LAMP2 expressed as the fraction of the 
total vesicular mIgG intensity colocalized with LAMP2 vesicles. Points show measurements from individual 
microvessels. Each symbol corresponds to a different animal. Lines show the mean ± SD for 33 microvessels 
from 3 different animals.
www.nature.com/scientificreports/
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The BBB poses a formidable obstacle for delivery of therapeutic antibodies since less than 0.1% of peripherally 
administered IgG reaches the brain parenchyma4. We show for the first time that a systemically administered 
antibody, Mab86, can be detected in vesicular structures within BECs. The low brain exposure of Mab86 and its 
colocalization with endogenous mIgG in BECs suggests that lysosomal clearance may limit Mab86 transport to 
Figure 3. Relocalization of intracellular mIgG to the abluminal membrane in pericyte-deficient mice.  
(a–c) Representative maximum projection images of brain microvessels (marked by CollagenIV in green) 
showing the localization of mIgG (red) in C57BL/6 (a) pdgf-bret/wt (b) and pdgf-bret/ret (c) mice. DAPI-stained 
nuclei are shown in blue. (d–f) Graphs showing the quantification of mIgG intensity per μ m2 of basal lamina  
(d) mIgG intensity per μ m3 of brain parenchyma (e) and number of vesicles per μ m3 of microvessel volume  
(f) in C57BL/6 (blue), pdgf-bret/wt (red), and pdgf-bret/ret mice (green). Points show measurements from individual 
microvessels. Each symbol corresponds to a different animal. Lines show the mean ± SD for 30 microvessels 
from 3 different animals for each phenotype. **p < 0.0001 by Fisher’s LSD test. (g) Representative maximum 
projection of a brain microvessel in pdgf-bret/ret mice showing the localization of mIgG (red) and lysosomes 
marked by LAMP2 (green). The right panel shows a high magnification of a single optical slice image of the 
boxed area and highlights the reduced colocalization between LAMP2 and mIgG. Individual mIgG and LAMP2 
vesicles are marked with arrowheads and arrows, respectively.
www.nature.com/scientificreports/
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the brain parenchyma. Loss of pericytes significantly enhanced Mab86 brain delivery as shown by substantially 
increased target engagement in neurons and, similar to endogenous mIgG, did not increase the number of intra-
cellular Mab86-positive vesicles in BECs. Overall our results suggest that pericytes regulate IgG transcytosis in 
part by controlling trafficking to lysosomes for degradation. Our data suggest that strategies to reduce IgG lysoso-
mal clearance in BECs may enhance delivery of antibodies across the BBB and into the brain.
Methods
Mice. TauPS2APP (3Tg) and pdgf-bret/ret mice were described previously17,21. 3Tg mice were crossed with pdgf-
bret/wt mice to generate 3Tgx pdgf-bret/ret and 3Tg x pdgf-bret/wt littermates. All animal experiments were approved 
by the Swiss Veterinary Office Basel-Stadt and were carried out in accordance with the approved guidelines 
described in the Swiss animal permission #1902.
Brain sectioning and immunofluorescence. Brain processing was performed as previously described19. 
Briefly, 19–20 months-old C57BL/6, pdgf-bret/wt or pdgf-bret/ret mice were euthanized with CO2 and transcardially 
perfused with PBS at 37 °C, followed by perfusion with 2% PFA. The brain was then removed and incubated 
overnight in 2% PFA at 4 °C before sectioning. Brains were included in 2% agarose and 100 μ m sagittal sections 
were cut using a Leica VT1000M vibratome. Sections were stored at −20 °C in 1:1 PBS/Glycerol. Sections were 
processed for immunofluorescence by washing with PBS and permeabilization with PBS 0.3% Triton X-100 and 
10% donkey serum for blocking. Primary antibodies were diluted in 5% donkey serum in PBS and incubated 
with sections for 72 hours at 4 °C, followed by washing with PBS and 1 hour incubation at room temperature 
with appropriate fluorescently-labelled secondary antibodies (Donkey anti-goat, donkey anti-rabbit, or donkey 
anti-rat IgG coupled to AlexaFluor488, 555, or 647, from LifeTechnologies) in 5% PBS. Finally, sections were 
Figure 4. Increase of intracellular and abluminal vesicles in pericyte-deficient mice. (a) Scheme 
representing the different vesicle populations identified by TEM in BECs. (b–d) representative TEM cross-
sections of brain microvessels in pdgf-bret/wt (left panel), and pdgf-bret/ret mice (right panel) showing coated and 
non-coated luminal vesicles (b) intracellular vesicles and tubules (c) and abluminal vesicles (d). (e–g) Graphs 
showing the quantification of the number of vesicles per capillary identified by TEM in pdgf-bret/wt (red), and 
pdgf-bret/ret mice (green). Points show measurements from individual microvessels. Each symbol corresponds 
to a different animal. Columns represent the median and error bars the interquartile range for at least 18 
microvessels from at least 3 different animals per phenotype. **p < 0.005 by Mann-Whitney U test.
www.nature.com/scientificreports/
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washed with PBS, stained with 1 μ g/ml DAPI and mounted using DAKO Fluorescent Mounting medium on glass 
slides with a 0.17 mm coverslip. Table 1 shows the list of antibodies used for the study.
Figure 5. Pericyte depletion results in increased target engagement of an antibody against phosphotau.  
(a,b) Representative maximum intensity projections of microcapillaries comparing the intracellular distribution 
of Mab86 (green) after acute injection and endogenous mIgG (red) in pdgf-bret/wt (a), and pdgf-bret/ret (b) mice. 
(c,d) High-resolution images of neurons on the hippocampus of 3Tg x pdgf-bret/wt (c) or 3Tg x pdgf-bret/ret (d) 
mice. In all images, DAPI-stained nuclei are shown in blue. (e,f) Representative low-magnification images of the 
hippocampus of 3Tg x pdgf-bret/wt (e) or 3Tg x pdgf-bret/ret (f) mice showing phosphotau positive neurons (red) 
and Mab86 (green). (g,h) High magnification images of the boxed area in 3Tg x pdgf-bret/wt (g) or 3Tg x pdgf-bret/ret  
(h) mice highlighting the accumulation of Mab86 in phosphotau positive neurons in 3Tg x pdgf-bret/ret mice.
www.nature.com/scientificreports/
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Electron microscopy. Brain samples were fixed by immersion in 2.5% glutaraldehyde and 2.5% paraform-
aldehyde in cacodylate buffer (0.1 M, pH 7.4) and washed in cacodylate buffer for 30 minutes. The samples were 
post-fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 1 hour at 4 °C and dehydrated through graded 
alcohol (50, 70, 90, and 100%) and propylene oxide for 30 minutes each. Next, samples were oriented longitudi-
nally and embedded in Epon 812. Ultrathin 70 nm sections were contrasted with uranyl acetate and lead citrate 
and examined at 70 kv with a Morgagni 268D electron microscope. Digital images were acquired with a Mega 
View III camera (Soft Imaging System). Cortical capillaries were selected randomly for quantification of intra-
cellular vesicles.
Imaging of intracellular mIgG at the NVU. Mounted brain sections were imaged using the Leica TCS 
SP8 microscope using a HC PL APO 63x/1.4 oil objective. Images were 12-bit and either 1024 × 1024 with 90 nm 
pixel size or 512 × 512 with 46.46 pixel size. Laser intensity and detector gain settings were optimized to mini-
mize pixel saturation and maximize dynamic range. Between 15 and 20 optical sections were acquired per vessel 
covering a z-distance of 7–12.5 μ m. Deconvolution of confocal images was performed using the Leica LAS-AF 
3D deconvolution tool. Movies and 3D reconstructions of vessels were performed using Imaris. Cross-sections 
were performed using FIJI.
Quantification of intracellular mIgG. Two different methods were used to quantify intracellular mIgG 
within BECs. Since the density of mIgG-positive structures was low and the z-stack acquired was only 7 μ m 
thick, we could analyze the maximum intensity projection of each microvessel. Quantitative multiparametric 
image analysis (QMPIA) was performed using Kalaimoscope MotionTracking as previously described18,28,29. 
Object-based colocalization was estimated after substraction of random colocalization as previously described30. 
To quantify and compare the accumulation of mIgG in intracellular vesicles, basal lamina and parenchymal space, 
quantification were performed using Imaris. 3D-reconstructed images were segmented using an absolute inten-
sity threshold mask on CollagenIV to identify intracellular structures (within CollagenIV mask), Basal Lamina 
(colocalized with CollagenIV mask) and parenchymal signal (outside of CollagenIV mask). Intracellular vesicles 
were segmented using Imaris spot detection algorithm with default parameters and an estimated diameter of 0.8 
μ m. mIgG intensity values were normalized by the surface area of the mask or the parenchymal volume. The total 
number of vesicles was normalized by the volume of CollagenIV mask. Quantifications were obtained from 10 
microvessels per animal using at least 3 animals per genotype. Multiple statistical comparisons were performed 
using Fisher’s LSD test in GraphPad.
Detection of BS or Mab86. 14-months old TAuPS2APP mice were injected with 6 mg/kg BS i.v. and eutha-
nized by pentobarbital 30 minutes after injection. Then, animals were transcardially perfused with PBS, followed 
by perfusion with 2% PFA. The brains were removed and incubated overnight in 2% PFA at 4 °C before section-
ing. For Mab86 detection, 13 months old 3Tg x pdgf-bret/wt or 3Tg x pdgf-bret/ret mice were injected with 30 mg/kg 
Mab86 and euthanized by pentobarbital 1 or 48 hours after injection. Whole brain images were acquired from fro-
zen sections prepared and immunostained with an anti-human PHF-TAU AT8 antibody and a goat anti-human 
IgG (H + L) AlexaFluor555 (LifeTechnologies) to detect Mab86 (Pierce, MN1020) as previously described20. 
Imaging was performed using a Metafer 4 slide scanning system (MetaSystems).
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